Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.
Infections caused by group A streptococcus (GAS) represent a public health problem in both developing and developed countries. The current available methods of prevention are either inadequate or ineffective, which is highlighted by the resurgence in invasive GAS infections over the past two decades. The management of GAS and associated diseases requires new and improved approaches. This review discusses various potential approaches in controlling GAS infections, ranging from prophylactic vaccines to antibody immunotherapy.
Bacterial Vaccines Laboratory, The Australian Centre for Vaccine Development, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston, Brisbane, Australia.
Manisha
M
Pandey
Silvana
S
Sekuloski
Michael R
MR
Batzloff
D006801:Humans; D007114:Immunization / Q000379:methods / Q000639:trends; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008854:Microscopy, Electron; D013290:Streptococcal Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013297:Streptococcus pyogenes / Q000276:immunology* / Q000648:ultrastructure; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology*
D022541:Streptococcal Vaccines; D022223:Vaccines, Subunit